Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 0.63 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572956 | 1.00 | CTSB (0.63) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL20204725 | 1.00 | CTSB (0.63) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL7144589 | 0.90 | CTSB (0.61) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL13706577 | 0.90 | CTSB (0.61) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL8259852 | 0.88 | CTSB (0.62) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL13933704 | 0.88 | CTSB (0.62) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL24178168 | 0.88 | CTSB (0.58) | CTSBCTSLPSMB5PSMB2CMA1 | |
| SCHEMBL30371890 | 0.88 | CTSB (0.58) | CTSBCTSLPSMB5PSMB2PSMB1 | |
| SCHEMBL24178174 | 0.88 | CTSB (0.58) | CTSBCTSLPSMB5PSMB2CMA1 | |
| SCHEMBL20204721 | 0.88 | CTSB (0.55) | CTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | CTSB 8/4885CTSL 34/4885PSMB5 518/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | CTSB 8/4885CTSL 34/4885PSMB5 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.